<p>Fayez Sarofim
&amp; Co 在最近向证券交易委员会提交的 13F 表格中表示，在第二季度将其在雅培（NYSE:ABT - 免费报告）股票的持有量降低了 2.2%。该基金在季度内出售了 99,447 股后，持有 4,522,297 股这家医疗产品制造商的股票。雅培在 Fayez Sarofim
&amp; Co 的投资组合中占约 1.5%，使其成为该基金的第 22 大持仓。截至最近的 SEC 文件，Fayez Sarofim
&amp; Co 持有的雅培股份约占 0.26%，价值 619,107,000 美元。</p>
<p>获取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>ABBV 股票：250 美元可能是大幅第三季度盈利超预期后的新底部</li>
</ul>
<p>其他几家对冲基金最近也对其在该公司的持仓进行了调整。IMG Wealth Management Inc. 在第二季度将其在雅培的持仓增加了 759.1%。IMG Wealth Management Inc. 现在持有 189 股这家医疗产品制造商的股票，价值 26,000 美元，此前在上个季度又增持了 167 股。Elequin Capital LP 在第一季度购买了雅培的新股份，价值约 30,000 美元。Anfield Capital Management LLC 在第二季度将其在雅培的持仓增加了 81.3%。Anfield Capital Management LLC 现在持有 232 股这家医疗产品制造商的股票，价值 32,000 美元，此前在此期间又购买了 104 股。Curio Wealth LLC 在第二季度将其在雅培的持仓增加了 15,250.0%。Curio Wealth LLC 现在持有 307 股这家医疗产品制造商的股票，价值 42,000 美元，此前在上个季度又购买了 305 股。最后，Pineridge Advisors LLC 在第二季度将其在雅培的持仓增加了 34.6%。Pineridge Advisors LLC 现在持有 315 股这家医疗产品制造商的股票，价值 43,000 美元，此前在此期间又购买了 81 股。目前，75.18% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>雅培股票表现</h2>
<p>周二，ABT 股票开盘价为 121.88 美元。该公司的市值为 2119.3 亿美元，市盈率为 15.27，PEG 比率为 2.28，贝塔值为 0.71。雅培的 52 周低点为 110.86 美元，52 周高点为 141.23 美元。该公司的速动比率为 1.24，流动比率为 1.70，债务股本比率为 0.23。公司的 50 日移动平均线为 128.31 美元，200 日移动平均线为 130.72 美元。</p>
<ul>
<li>雅培十月股价暴跌是买入信号</li>
</ul>
<p>雅培（NYSE:ABT - 获取免费报告）最近于 10 月 15 日（星期三）公布了其财报。这家医疗产品制造商报告本季度每股收益（EPS）为 1.30 美元，符合市场共识预期的 1.30 美元。雅培的股本回报率为 17.60%，净利润率为 31.88%。该公司的季度收入为 113.7 亿美元，而分析师预期为 114 亿美元。去年同期，该公司每股收益为 1.21 美元。该公司的季度收入同比增长 6.9%。雅培已将其 2025 财年的指导目标设定为每股收益 5.120-5.180 美元。平均而言，卖方分析师预计雅培在当前财年将发布每股收益 5.14 美元。</p>
<h2>雅培股息公告</h2>
<p>该公司最近还宣布了季度股息，已于 11 月 17 日（星期一）支付。10 月 15 日（星期三）登记在册的股东获得了 0.59 美元的股息。除息日期为 10 月 15 日（星期三）。这代表着年化股息为 2.36 美元，收益率为 1.9%。雅培的派息比率目前为 29.57%。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>为什么雅培在 2025 年第二季度是一个买入机会：增长与收益</li>
</ul>
<p>多家研究分析师对该股票发表了看法。Raymond James Financial 将雅培股票的目标价从 141.00 美元上调至 146.00 美元，并在 10 月 16 日的研究报告中给予该公司 “跑赢大盘” 的评级。大和资本市场将雅培股票的目标价从 134.00 美元上调至 136.00 美元，并在 10 月 21 日的报告中给予该公司 “跑赢大盘” 的评级。Evercore ISI 将雅培股票的目标价从 144.00 美元下调至 142.00 美元，并在 10 月 15 日的研究报告中对该股票给予 “跑赢大盘” 的评级。William Blair 在 11 月 20 日的研究报告中将雅培升级为 “强力买入” 评级。最后，富国银行将雅培的目标价从 142.00 美元上调至 146.00 美元，并在 10 月 16 日的报告中给予该股票 “增持” 的评级。两位研究分析师对该股票给予 “强力买入” 评级，十七位给予 “买入” 评级，四位给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 147.00 美元。</p>
<p><strong>查看我们最新的雅培股票报告</strong></p>
<h2>雅培公司简介</h2>
<p>（免费报告）</p>
<p>雅培及其子公司在全球范围内发现、开发、制造和销售医疗产品。它分为四个部门：成熟药品、诊断产品、营养产品和医疗器械。该公司提供用于治疗胰腺外分泌功能不全、肠易激综合症或胆道痉挛、肝内胆汁淤积或抑郁症状、妇科疾病、激素替代疗法、血脂异常、高血压、甲状腺功能减退、梅尼埃病和前庭性眩晕、疼痛、发热、炎症和偏头痛的仿制药，以及提供抗感染药物克拉霉素、流感疫苗和调节结肠生理节律的产品。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，胜过雅培</li>
<li>如何投资蓝筹股</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑对消费者健康的启示</li>
<li>什么是特别股息？</li>
<li>2026 年最有可能拆分的三只股票</li>
<li>如何投资小盘股</li>
<li>ChargePoint 的复苏故事：为什么这只电动车股票再次充满活力</li>
</ul>
<p><strong>想看看其他对雅培持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取雅培（NYSE:ABT - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在雅培吗？</h2>
<p>在你考虑雅培之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而雅培并不在名单上。</p>
<p>虽然雅培目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

雅培

<p>Fayez Sarofim & Co 在第二季度减少了对雅培的持股，减持幅度为 2.2%，出售了 99,447 股。雅培的股票开盘价为 121.88 美元，市值为 2119.3 亿美元。分析师预测公司将实现增长，目标股价范围在 134 美元到 146 美元之间。雅培第三季度的收益符合预期，公司宣布每股季度分红为 0.59 美元。由于增长和收益潜力，该股票被认为在 2025 年第二季度值得买入</p>

<p>Fayez Sarofim &amp; Co lowered its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 2.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The fund owned 4,522,297 shares of the healthcare product maker's stock after selling 99,447 shares during the quarter. Abbott Laboratories accounts for about 1.5% of Fayez Sarofim &amp; Co's portfolio, making the stock its 22nd largest position. Fayez Sarofim &amp; Co owned about 0.26% of Abbott Laboratories worth $619,107,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Fayez Sarofim
&amp; Co 在最近向证券交易委员会提交的 13F 表格中表示，在第二季度将其在雅培（NYSE:ABT - 免费报告）股票的持有量降低了 2.2%。该基金在季度内出售了 99,447 股后，持有 4,522,297 股这家医疗产品制造商的股票。雅培在 Fayez Sarofim
&amp; Co 的投资组合中占约 1.5%，使其成为该基金的第 22 大持仓。截至最近的 SEC 文件，Fayez Sarofim
&amp; Co 持有的雅培股份约占 0.26%，价值 619,107,000 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>ABBV 股票：250 美元可能是大幅第三季度盈利超预期后的新底部</li>
</ul>
</div><p>Several other hedge funds have also recently made changes to their positions in the business. IMG Wealth Management Inc. grew its position in Abbott Laboratories by 759.1% in the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker's stock worth $26,000 after acquiring an additional 167 shares in the last quarter. Elequin Capital LP bought a new stake in shares of Abbott Laboratories in the 1st quarter valued at approximately $30,000. Anfield Capital Management LLC boosted its holdings in shares of Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker's stock worth $32,000 after purchasing an additional 104 shares during the period. Curio Wealth LLC increased its position in shares of Abbott Laboratories by 15,250.0% during the 2nd quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker's stock valued at $42,000 after purchasing an additional 305 shares during the last quarter. Finally, Pineridge Advisors LLC raised its holdings in Abbott Laboratories by 34.6% during the 2nd quarter. Pineridge Advisors LLC now owns 315 shares of the healthcare product maker's stock valued at $43,000 after buying an additional 81 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他几家对冲基金最近也对其在该公司的持仓进行了调整。IMG Wealth Management Inc. 在第二季度将其在雅培的持仓增加了 759.1%。IMG Wealth Management Inc. 现在持有 189 股这家医疗产品制造商的股票，价值 26,000 美元，此前在上个季度又增持了 167 股。Elequin Capital LP 在第一季度购买了雅培的新股份，价值约 30,000 美元。Anfield Capital Management LLC 在第二季度将其在雅培的持仓增加了 81.3%。Anfield Capital Management LLC 现在持有 232 股这家医疗产品制造商的股票，价值 32,000 美元，此前在此期间又购买了 104 股。Curio Wealth LLC 在第二季度将其在雅培的持仓增加了 15,250.0%。Curio Wealth LLC 现在持有 307 股这家医疗产品制造商的股票，价值 42,000 美元，此前在上个季度又购买了 305 股。最后，Pineridge Advisors LLC 在第二季度将其在雅培的持仓增加了 34.6%。Pineridge Advisors LLC 现在持有 315 股这家医疗产品制造商的股票，价值 43,000 美元，此前在此期间又购买了 81 股。目前，75.18% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Abbott Laboratories Stock Performance</h2>
<div class="lb-trans"><h2>雅培股票表现</h2>
</div><p>Shares of ABT stock opened at $121.88 on Tuesday. The firm has a market cap of $211.93 billion, a price-to-earnings ratio of 15.27, a PEG ratio of 2.28 and a beta of 0.71. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The company's 50 day moving average is $128.31 and its 200 day moving average is $130.72.</p>
<div class="lb-trans"><p>周二，ABT 股票开盘价为 121.88 美元。该公司的市值为 2119.3 亿美元，市盈率为 15.27，PEG 比率为 2.28，贝塔值为 0.71。雅培的 52 周低点为 110.86 美元，52 周高点为 141.23 美元。该公司的速动比率为 1.24，流动比率为 1.70，债务股本比率为 0.23。公司的 50 日移动平均线为 128.31 美元，200 日移动平均线为 130.72 美元。</p>
</div><ul>
<li>Abbott Laboratories' October Price Plunge Is a Signal to Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培十月股价暴跌是买入信号</li>
</ul>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.30. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The business had revenue of $11.37 billion for the quarter, compared to analysts' expectations of $11.40 billion. During the same quarter last year, the firm earned $1.21 EPS. The business's revenue for the quarter was up 6.9% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 获取免费报告）最近于 10 月 15 日（星期三）公布了其财报。这家医疗产品制造商报告本季度每股收益（EPS）为 1.30 美元，符合市场共识预期的 1.30 美元。雅培的股本回报率为 17.60%，净利润率为 31.88%。该公司的季度收入为 113.7 亿美元，而分析师预期为 114 亿美元。去年同期，该公司每股收益为 1.21 美元。该公司的季度收入同比增长 6.9%。雅培已将其 2025 财年的指导目标设定为每股收益 5.120-5.180 美元。平均而言，卖方分析师预计雅培在当前财年将发布每股收益 5.14 美元。</p>
</div><h2>Abbott Laboratories Dividend Announcement</h2>
<div class="lb-trans"><h2>雅培股息公告</h2>
</div><p>The company also recently announced a quarterly dividend, which was paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th were issued a $0.59 dividend. The ex-dividend date was Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.9%. Abbott Laboratories's payout ratio is currently 29.57%.</p>
<div class="lb-trans"><p>该公司最近还宣布了季度股息，已于 11 月 17 日（星期一）支付。10 月 15 日（星期三）登记在册的股东获得了 0.59 美元的股息。除息日期为 10 月 15 日（星期三）。这代表着年化股息为 2.36 美元，收益率为 1.9%。雅培的派息比率目前为 29.57%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Why Abbott Laboratories Is a Q2 2025 Buy: Growth &amp; Yield</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么雅培在 2025 年第二季度是一个买入机会：增长与收益</li>
</ul>
</div><p>A number of research analysts have weighed in on the stock. Raymond James Financial boosted their price objective on shares of Abbott Laboratories from $141.00 to $146.00 and gave the company an &#34;outperform&#34; rating in a research report on Thursday, October 16th. Daiwa Capital Markets upped their price target on shares of Abbott Laboratories from $134.00 to $136.00 and gave the company an &#34;outperform&#34; rating in a report on Tuesday, October 21st. Evercore ISI reduced their price objective on shares of Abbott Laboratories from $144.00 to $142.00 and set an &#34;outperform&#34; rating on the stock in a research report on Wednesday, October 15th. William Blair upgraded Abbott Laboratories to a &#34;strong-buy&#34; rating in a research report on Thursday, November 20th. Finally, Wells Fargo &amp; Company increased their price target on Abbott Laboratories from $142.00 to $146.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $147.00.</p>
<div class="lb-trans"><p>多家研究分析师对该股票发表了看法。Raymond James Financial 将雅培股票的目标价从 141.00 美元上调至 146.00 美元，并在 10 月 16 日的研究报告中给予该公司 “跑赢大盘” 的评级。大和资本市场将雅培股票的目标价从 134.00 美元上调至 136.00 美元，并在 10 月 21 日的报告中给予该公司 “跑赢大盘” 的评级。Evercore ISI 将雅培股票的目标价从 144.00 美元下调至 142.00 美元，并在 10 月 15 日的研究报告中对该股票给予 “跑赢大盘” 的评级。William Blair 在 11 月 20 日的研究报告中将雅培升级为 “强力买入” 评级。最后，富国银行将雅培的目标价从 142.00 美元上调至 146.00 美元，并在 10 月 16 日的报告中给予该股票 “增持” 的评级。两位研究分析师对该股票给予 “强力买入” 评级，十七位给予 “买入” 评级，四位给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 147.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Abbott Laboratories</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的雅培股票报告</strong></p>
</div><h2>Abbott Laboratories Company Profile</h2>
<div class="lb-trans"><h2>雅培公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p>
<div class="lb-trans"><p>雅培及其子公司在全球范围内发现、开发、制造和销售医疗产品。它分为四个部门：成熟药品、诊断产品、营养产品和医疗器械。该公司提供用于治疗胰腺外分泌功能不全、肠易激综合症或胆道痉挛、肝内胆汁淤积或抑郁症状、妇科疾病、激素替代疗法、血脂异常、高血压、甲状腺功能减退、梅尼埃病和前庭性眩晕、疼痛、发热、炎症和偏头痛的仿制药，以及提供抗感染药物克拉霉素、流感疫苗和调节结肠生理节律的产品。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>How to Invest in Blue Chip Stocks</li>
<li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li>
<li>What is a Special Dividend?</li>
<li>3 Stocks Most Likely to Split in 2026</li>
<li>How to Invest in Small Cap Stocks</li>
<li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过雅培</li>
<li>如何投资蓝筹股</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑对消费者健康的启示</li>
<li>什么是特别股息？</li>
<li>2026 年最有可能拆分的三只股票</li>
<li>如何投资小盘股</li>
<li>ChargePoint 的复苏故事：为什么这只电动车股票再次充满活力</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对雅培持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取雅培（NYSE:ABT - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在雅培吗？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑雅培之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而雅培并不在名单上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然雅培目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Fayez Sarofim & Co 出售了 99,447 股雅培公司（Abbott Laboratories）的股票，股票代码为$ABT